# Sprint Bioscience > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/sprintbioscience). ## Overview Sprint Bioscience is a Swedish biopharmaceutical company focused on discovering and developing preclinical cancer drug programs. The company builds its portfolio in Stockholm and Huddinge, where it advances internally generated oncology programs that are intended to be partnered out to international pharmaceutical companies. ## Products & services • Preclinical oncology drug discovery programs • Fragment-based drug discovery platform • Cancer metabolism programs • Tumor microenvironment programs • Immune evasion / immuno-oncology programs • Out-licensing and strategic partnering of programs - **Preclinical oncology programs** (55%) — Internally generated cancer drug programs advanced through discovery and preclinical development. - **Strategic partnering and licensing** (35%) — Licensing and collaboration agreements that monetize programs through partners. - **Research and milestone income** (10%) — Research funding, milestone payments, and other partner-related program income. - Preclinical oncology drug discovery programs - Fragment-based drug discovery platform - Cancer metabolism programs - Tumor microenvironment programs - Immune evasion / immuno-oncology programs - Out-licensing and strategic partnering of programs ## Customers Sprint Bioscience sells primarily to international pharmaceutical and biotech companies that license preclinical programs or enter strategic partnerships. Its counterparties also include research partners and organizations that fund discovery work through collaborations or milestone-based agreements. The company’s customer base is therefore concentrated in external partners that want de-risked oncology assets rather than end patients or hospitals. - **International pharmaceutical companies** (primary) — License preclinical cancer programs and pay for access to differentiated assets. - **Biotechnology partners** (primary) — Enter collaborations or option deals around specific discovery programs. - **Research and development collaborators** (secondary) — Provide research funding or milestone support tied to program progress. - Global pharma companies seeking preclinical oncology assets - Biotech partners looking for licensed discovery-stage programs - Collaborators funding research and milestone-based development - Partners that value first-in-class or differentiated cancer targets - Counterparties that want external innovation without building it in-house ## Geography Sprint Bioscience is headquartered in Stockholm and operates from Huddinge, near Karolinska University Hospital and Karolinska Institutet. Its business is built around partnering with international companies, so commercial exposure is broader than Sweden even though the scientific base is Swedish. The company’s revenue exposure is tied to where its licensing and collaboration counterparties are located rather than to local healthcare demand. - Headquartered in Stockholm, Sweden - Operations based in Huddinge near Karolinska institutions - Commercial partners are international rather than purely domestic - Revenue exposure follows licensing counterparties and collaboration geography - Swedish cost base with global partner-facing business model ## Strategy The company’s strategy is to identify promising oncology biology, build preclinical programs, and partner each program with an external pharmaceutical company. It emphasizes a portfolio approach across several cancer-relevant biology areas so that multiple assets can create multiple future revenue streams. Maintaining a strong financial position is important because it supports continued portfolio build-out and improves negotiating leverage in partnering discussions. - **Advance preclinical oncology assets to partnering stage** (short-term) — Partnering is the core monetization model for each program. - **Broaden the program portfolio across key biology areas** (medium-term) — A diversified pipeline increases the chance of repeat deal flow. - **Maintain financial strength for development continuity** (medium-term) — Discovery-stage biotech needs funding to sustain long development cycles. - Advance internally generated cancer programs to partnering stage - Build a portfolio across multiple oncology biology areas - Use strategic partnerships to monetize preclinical assets - Create multiple future revenue streams from one platform - Preserve financial flexibility to strengthen deal leverage ## Risks Sprint Bioscience faces the typical risks of preclinical biotech: scientific failure, long development timelines, and dependence on partner interest to convert programs into revenue. It also has exposure to counterparty, funding, and currency risk because income is largely partnership-based and often received in USD while costs are mainly in SEK. - **Development failure in preclinical programs** [high] — Discovery-stage assets can fail on biology, safety, or commercial fit before monetization. - **Partner and counterparty dependence** [high] — The business model relies on strategic partners to generate licensing and milestone income. - **Liquidity and financing needs** [high] — Research and drug development require ongoing funding before product revenue exists. - **Foreign exchange risk** [medium] — Reportedly, revenues are mainly in USD while a large share of costs is in SEK. - **Regulatory and industry change** [medium] — Oncology drug development is affected by evolving scientific, legal, and regulatory standards. - Drug discovery programs may fail before reaching partnering or licensing - Revenue depends on external partners signing and continuing agreements - Funding risk is material because development is capital intensive - USD revenues and SEK costs create foreign exchange exposure - Regulatory and market changes can affect oncology partnering demand ## Accounting The most important accounting issues are revenue recognition for licensing, research funding, and milestone payments, which can create uneven timing of reported sales. The company also has judgment-heavy estimates around development-related assets, potential impairment, and lease accounting under RFR 2/IFRS-related disclosures, all of which can affect comparability across periods. - **Revenue recognition for licensing and milestones** — Affects quarterly comparability and reported sales timing - **Impairment and valuation of development assets** — Can materially affect operating result - **Lease accounting under RFR 2 / IFRS 16 disclosure** — Affects balance sheet presentation and leverage perception - **Foreign currency effects** — Can move operating result without underlying business change - License and milestone revenue timing can shift reported sales between periods - Research funding and partner payments may depend on contract milestones - Development-stage assets require judgment on capitalization and impairment - Lease disclosures matter because IFRS 16 would change assets and liabilities - Foreign currency translation affects reported results because revenue is often in USD --- *Last updated: 2026-08-11T04:04:55.925850+00:00*